Table I.
Demographics, Baseline Clinical Characteristics, and Exposure to Study Medication (Safety Population)
| Sumatriptan/Naproxen Sodium | Sumatriptan | Naproxen | |
|---|---|---|---|
| Baseline clinical characteristics | |||
| Mean age, y (SD) | 38.9 (11.6) | 39.7 (11.2) | 39.2 (11.7) |
| Women, No. (%) | 98 (77) | 104 (87) | 105 (83) |
| Race, No. (%) | |||
| White | 112 (88) | 104 (87) | 113 (89) |
| Black | 13 (10) | 11 (9) | 11 (9) |
| Asian | 2 (2) | 3 (3) | 3 (2) |
| American Indian/Alaska native | 0 (0) | 1 (<1) | 0 (0) |
| Asian and white | 0 (0) | 1 (<1) | 0 (0) |
| Migraine type, No. (%) | |||
| With aura only | 32 (25) | 30 (25) | 37 (29) |
| Without aura only | 70 (55) | 67 (56) | 75 (59) |
| Both with and without aura | 25 (20) | 23 (19) | 15 (12) |
| Mean migraine attacks per mo (SD) | 4.5 (1.8) | 4.1 (1.7) | 4.6 (1.8) |
| Mean age at onset of migraine, y (SD) | 21.1 (10.8) | 20.0 (10.4) | 24.3 (11.7) |
| Mean clinic BP, mm Hg (SD) | |||
| Systolic | 108.3 (9.3) | 109.6 (9.6) | 108.6 (9.2) |
| Diastolic | 71.0 (6.9) | 71.6 (7.2) | 71.4 (7.3) |
| Mean self‐BP, mm Hg (SD) | |||
| Systolic | 111.7 (9.0) | 110.8 (9.2) | 110.1 (9.2) |
| Diastolic | 76.0 (6.8) | 75.7 (7.4) | 74.7 (7.0) |
| Exposure to study medication | |||
| Mean number of doses (SD) | 18.3 (15.5) | 19.0 (19.6) | 16.6 (13.6) |
| Mean number of days on treatment (SD) | 14.1 (11.4) | 14.8 (15.3) | 11.6 (9.3) |
Abbreviations: BP, blood pressure; SD, standard deviation.